VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
Multiple Myeloma is a incurable disease. Recently developed targeted therapy gave new hope
for the patients with multiple myeloma. Velcade in combination with other agents are
currently in trials for the newly diagnosed patient, we designed sequential treatment with
VTD and MPT for the patients who are not transplant candidates. This would be expected to
result in maximal tumor control, and thus, in maximal survival benefit, equivalent to high
dose therapy with autologous transplantation in younger population